Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice find , also that it is listed as Enzolytics not the subs. Thanks again for a positive find. GLTA
I think it might go back to the suit in 2022 that was dismissed.Peter is refiling in another district.
Before me is Defendant's motion to dismiss pursuant to Rule 12(b)(6) (D.I. 7) and Plaintiffs cross-motion for the court to set bond and compel Defendant to reissue shares pursuant to Plaintiff posting bond. (D.I. 17). I have reviewed the parties' briefing. (D.I. 8, 17, 20). For the reasons set forth below, Defendant's motion is GRANTED and Plaintiffs cross-motion is DENIED.
I. BACKGROUND
Plaintiff Peter Mergenthaler filed suit against Defendant Enzolytics, Inc. (“ENZC”) on August 11, 2021, asserting, “[Defendant] should be ordered to reissue to [Plaintiff] 10,000,000 of its shares” pursuant to 6 Del. C. § 8-405. (D.I. 1 at ¶¶35-51, 51).
Plaintiff states that he owns 10,000,000 shares of ENZC, but that James W. Zimbler engaged in a scheme to fraudulently convert Plaintiffs shares to his and others' ownership. (Id. at ¶¶9-26). Specifically, Plaintiff states that, beginning in 2015, Zimbler orchestrated the fraudulent transfer of Plaintiff s shares in ECOP, which is a predecessor corporation of ENCZ, to Sage Market Advisors (2,500,000 shares), OMS Consulting, Inc. (1,500,000 shares), M. Lamar Outz (1,000,000 shares), and American Asset Management Services Corporation (5,000,000 shares). (Id. at ¶¶3,22-26,40). Zimbler owns American Asset Management Services Corporation, to which 5,000,000 of Plaintiffs shares were transferred. (Id. at ¶¶26, 41). At the time of this transfer, Zimbler was the vice president of ECOP. (Id. at¶37). Zimbler resigned from his position at ECOP on July 6, 2015, after the conversion of Plaintiff s shares. (Id. at 38.)
Defendant requests that this court dismiss Plaintiffs suit pursuant to Rule 12(b)(6) for Plaintiffs failure to comply with 6 Del C. § 8-405. (D.I. 8). In a cross-motion, Plaintiff requests that this court set a sufficient indemnity bond compliant with 6 Del. C. § 8-405(a)(2) and order Defendant to reissue 10,000,000 ENCZ shares to Plaintiff. (D.I. 17 at 1, 7-8).
Thanks was looking for a seperate filing for that .
Sorry must have missed that since the SEC doesnt show anything. I see a section that has the 50m shares mentioned for voting rights just didnt see a filing for it.GLTA
https://www.sec.gov/edgar/browse/?CIK=0001855351
Maybe I shouldn't have used cash influx ( but something has to be able to support the added shares to keep the SP @ 10.00 that would be the PIPE money that would hold the value at 450m) , This was the point I was trying to point out.They have to report
Yes, a company listed on NASDAQ has to report an increase in outstanding shares. According to the Nasdaq Listing Center, companies applying to list and listed on Nasdaq must meet the qualitative requirements outlined in the Rule 5600 Series1. In addition to meeting the quantitative requirements in the Rule 5200, 5300, 5400 and 5500 Series1, companies must meet all of the criteria under a particular set of standards2. Each listing firm must adhere to U.S. Securities and Exchange Commission (SEC) Marketplace Rules for Nasdaq listings, including corporate governance rules 4350, 4351, and 43602. The regular bid price of shares of the company’s stock at the time of listing must be at least $4.00; however, a company may qualify under a closing price alternative of $3.00 or $2.00 if the company meets varying requirements2. Companies must have a minimum of 1,250,000 publicly traded shares outstanding upon listing, excluding those held by officers, directors, or any beneficial owners of more than 10% of the company2. To stay listed on the Nasdaq, a company must continue to meet the minimum listing requirements or risk being delisted and removed from the Nasdaq exchange2.
Learn more:
1. listingcenter.nasdaq.com
2. investopedia.com
3. listingcenter.nasdaq.com
4. sec.gov
https://securities-law-blog.com/2021/12/14/nasdaq-updated-las-form/
Just trying to connect dots from the past and what we are seeing currently. The facts not wishful thinking or misleading items being showed as fact but can't be proven by the poster. We all are here to make money and support a company that has cutting edge technology from their own posting, now it is down to a countdown to see if SAGA can file paperwork that the SEC and NASDAQ will accept after a vote of the shareholders to keep the SPAC alive.
The thing to really watch as many have been posting that SAGA increased in market cap if so at some point that value will have to be justified or it will drop due to it. Would SAGA been required to file a 8k to disclose the influx of cash for such an increase in the market cap? If the management of ENZC been issued shares ( which I don't think has happened ) would the date of said transaction of shares being issued to them be the date of record for dividends since that would be part of the deal that would invole ENZC shareholders? Again the post from GFand others showing they have their shares I believe is a mockup of what SAGA structure would look like if deal goes thru. If they do have the shares issued to them then why would they need more time and the SPAC to be extendend because the ink would be dry at this point. You don't give someone something ahead of time hoping that the deal will be extended if so that is just another case that SAGA isn't the right company to deal with. Kinda the samething ENZC did in the past gave shares ahead of time and then didn't get what they thought would be provided.
The latest data for Sagaliam Acquisition Corp (SAGA) on NASDAQ is as follows1:
Price: $11.06
Price Change: -$0.04
Price Change Percent: -0.3604%
Market Cap: $545,770,500
Accumulated Volume: 21,959
Average Volume: 850
Last Traded: October 27, 04:00 PM EDT
Please note that this information is subject to change as the market fluctuates.
Learn more:
1. bing.com
2. nasdaq.com
3. finance.yahoo.com
4. wise.com
5. google.com
+1 more
https://finance.yahoo.com/quote/saga/
Thanks I hadn't heard anything about the funding from the past either. So my question of the involvement of another company that maybe is still providing funding would want something in return for the funding they have provided to date noone is talking about. Just another piece of the puzzle that would need addressing. GLTA
I am asking about the funding from 2021 has nothing to do with NASDAQ or this deal that we have been told , if the sell goes thru for the two sub companies and ENZC will have nothing as many have stated. Then ITV-1 would go with the sale. This taking from links I provided earlier today
The clinical trials will be funded fully by the Company's European partners in IMPL. None of the clinical trials costs will be borne by the Company.
No I am not referncing the PIPE , I am talking about the business deal that was made to fund the EU ITV-1 in 2021 , where did they go or are they still funding it. If so I would say the will be asking some questions especially if the ITV-1 goes to another company by way of sale as it has been implied.
Question I don't think anyone has brought up. What do you think the business partnership that was promoted by Enzolytics that would fund the EU trials 100%, no money from Enzolytics will be needed is thinking at this point. What do they get out of this deal SAGA is proposing? If they are still funding the trials in EU would there have to be sometype of compensation to them / what will that be? Posting is old , but haven't seen that that deal went away for the funding and Enzolytics hasn't said they have been covering the cost. The reads imply that trials would be completed soon date of PRs 2021. GLTA
https://www.biospace.com/article/releases/enzolytics-announces-its-progress-toward-completion-of-clinical-trials-for-its-anti-hiv-itv-1-therapeutic-and-plans-for-its-distribution-throughout-europe/#:~:text=The%20clinical%20trials%20will%20be%20funded%20fully%20by,trials%20costs%20will%20be%20borne%20by%20the%20Company.
https://finance.yahoo.com/news/enzolytics-reports-engagement-scendea-usa-123000633.html.
https://www.biospace.com/article/releases/enzolytics-announces-its-progress-toward-completion-of-clinical-trials-for-its-anti-hiv-itv-1-therapeutic-and-plans-for-its-distribution-throughout-europe/#:~:text=The%20clinical%20trials%20will%20be%20funded%20fully%20by,trials%20costs%20will%20be%20borne%20by%20the%20Company.
All good don't argue with people throwout facts and if they can show a difference with facts always open and welcome. What should be looked at is the statement CC said if we don't put out a PR ourselves then don't count it as truth. So for all think about that , SAGA a company that is not current with anything puts out PR's but nothing from Enzolytics. So if you follow CC statement nothing is facts yet. GLTA
No you have been saying 9k shares for every 100k shares , I am saying 9k dollars worth for every 100k shares. Big difference . Have you found your example to show what you remember GLTA
Enjoy your weekend everyone , nothing is going to change over the next two days atleast .
Sorry but you are incorrect , Let us know what you find. Do you think people would be a little sour on a deal that would give them 90k for every 100k shares , instead it will be more like 9k for 100k shares held. GLTA
BM the example was 900-1200 for every 100k shares
It would have to be after Sept 6 2023 , I just found the delay mentioned in a Sept 6 PR saying it would be coming .GLTA
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/)
Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. The results of this African pilot clinical trial will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024.
so what are we missing we were told in 2021 clinical trials according to this PR
for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency
PUBLISHED
JUL 29, 2021 7:30AM EDT
COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization.
Production of the therapeutic will be accomplished at Danhson pharmaceutical company facilities, to be followed by clinical trials conducted by Clinic Design. Production of the therapeutics is expected to be completed in the next few months followed by clinical trials to be conducted immediately thereafter. The protocol of the trials will be guided by Pharmalex (https://www.pharmalex.com/), an EU regulatory consulting company.
Earlier in the year, the Company announced the formation of International Medical Partners ("IMPL"), a Bulgarian Limited Liability Company, of which the Company is 50% owner. Pursuant to that formation, the Company will fund the initial production of the ITV-1 therapeutic and the Company's partners in IMBL will fund the cost of the clinical trials and cost of EMA permitting.
IMBL will be the exclusive distributor of the ITV-1 therapeutic in the European Medicines Agency member countries (namely all 27 European Union member states and Iceland, Liechtenstein and Norway) as well as the countries of Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia and Lithuania. IMBL may distribute the ITV-1 therapeutic outside of its exclusive territory where an exclusive license does not otherwise exist.
All documentation for registration of IMPL has been filed with the Registry Office in Sofia. The initial funding of IMBL, by Enzolytics and its partners, has been provided by the partners.
The Company's two-year audit is proceeding in accordance with GAAP requirements and will be completed and filed as soon as completed. The audit is proceeding as planned without any unanswered issues.
Harry Zhabilov, CSO of Enzolytics, stated, "We are excited about the progress we have made with the assistance of our IMBL partners. Contracting with Danhson, Clinic Design and PharmaLex is integral to the success of the EMA permitting process. As this is the second time our ITV-1 therapeutic has progressed through clinical trials and the first trials were successful, we are fully confident that we will succeed in the permitting process. With the reciprocal treaty between the EMA and FDA, we believe that the EMA approval with lead to further advancement of our ITV-1 as a successful therapy."
This is the last two updates about why Africa hasn't started
https://finance.yahoo.com/news/enzolytics-offers-virogentics-inc-itv-145500819.html
Virogentics, Inc. Receives Permit for Export to Africa of the ITV-1 Immunotherapy Solidifying the Scheduled Administration of the Treatment
ALLEN, TX / ACCESSWIRE / August 8, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/)
Virogentics, Inc. ("VIRO") a wholly owned subsidiary of Enzolytics, Inc. (the "Company" or "ENZC"), a drug development biotech company, announced today the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC. The results of this African pilot clinical trial will be used in the development of the European Medicine Authority (EMA) clinical trials expected to begin in late 2023/early 2024.
Additionally, VIRO acknowledges the announcement by Sagaliam Acquisition Corp, ("NASDAQ:SAGA") that they had notified Continental Stock and Transfer Company that it was exercising the option to extend the time available to consummate a business combination agreement by an additional month to August 23, 2023. VIRO reports that substantial progress has been made on the combination agreement.
Barry Kostiner, the CEO of Sagaliam, stated "The VIRO team has done a great job of moving forward on their clinical and regulatory milestones. We are getting involved at the right time to provide the resources needed to build a platform for helping many people in Africa, Europe and globally."
Harry Zhabilov, Chief Scientific Officer of VIRO, stated "Every day we move closer to the ultimate goal of administering our immunotherapy to patients who we believe will benefit greatly from our technology, as well as the funding that will be unlocked by moving to NASDAQ."
Then you have this last update
Start Date is expected by the end of 2023 / beginning of 2024.
VIRO also offers an update on Diabetic trials and Sagaliam transaction.
ALLEN, TX / ACCESSWIRE / September 6, 2023/?Enzolytics, Inc. (OTC PINK: ENZC) (https://enzolytics.com/).
Virogentics, Inc. (“VIRO”), a wholly owned subsidiary of Enzolytics, Inc. (the “Company” or “ENZC”), a drug development biotech company, announced today that based on the Bulgarian population of HIV-infected individuals that the sample size for the ITV-1 clinical trials will be 60 individuals.
R&D Services Ltd. ("R&D"), under the leadership of Aneliya Vidinlieva, Manager Clinical Trials, assisted by Dr. Ivaylo Tsonev, Chief Medical Officer of Desing and three consultants assigned by the University of Pharmacology, will be performing the clinical trials. R&D and VIRO expect the clinical trials to begin in late 2023 or early 2024.
With locations across Bulgaria, where the Clinical Trials will be conducted, R&D services will manage all the administration of the Clinical Trials of ITV-1 conducted in public, municipal, and private healthcare institutions. R&D is certified to ISO 9001:2015, ISO 27001:2013, and ISO 14001:2015 quality assurance standards for services provided
R&D Services Ltd.’s general responsibilities include but are not limited to the following:
Improving the quality of the collected data during the clinical trials.
Building up a trial site at each healthcare institution and providing all the necessary equipment for conducting clinical trials and premises for proper document and study drugs storage, in compliance with the Good Documentation Practice, Good Clinical Practice, and Good Manufacturing Practice.
Ensuring protocol compliance, compliance with the International Conference on Harmonisation – Good Clinical Practice guideline, Bulgarian legislation and specific requirements of the Sponsor/CRO.
Providing the necessary documents for the initial study submission.
Prescreening of eligible patients during the initial review/approval period so that a maximum number of patients can be enrolled in the relevant time period.
Redirecting eligible patients from trial sites that do not participate in the trial to sites that are approved; building a referral network of physicians to support the study enrollment.
Quality checking all the needed documentation concerning the proper conduct of a clinical study (eCRF, temperature logs, subject logs, study drug accountability logs).
Reporting any adverse events to the Sponsor/CRO.
Ensuring document access for audits on behalf of the Sponsor/CRO, independent auditor, and regulatory authorities.
In addition, the trials being conducted by R&D will include a review by an immunologist to evaluate any correlation of patient outcomes with a different origin of immune deficiency using cell examination.
The Company’s therapeutic developments will include participation by many established pharm entities, including the following. VETPROM AD, a division of the French company Danhson, currently headed by Stanislav Stoev, Executive Director, represents over 65 years of continuous operations in the Bulgarian economy and is one of the largest pharmaceutical manufacturers of medicinal products (for human and veterinary use), food supplements and cosmetics in Bulgaria. VETPROM manufactures products under its brand name, as well as for third parties under contract manufacture agreements operating under accepted ISO 9001:2008 System for quality of management and the integrated system for Good Manufacturing Practice, under requirements of Volume 4, Good manufacturing practice (GMP) Guidelines.
The German Cooperative Clinical Grug Research and Development (CCDRD) is a contract research organization for clinical phase I-IV trials and will be performing the pharmacokinetics study on ITV-1 under the guidance and leadership of the CEO Rossen Koytchev, MD, PhD and Petra Kowalski PhD, Director of Business Development. CCDRD was founded in 1990 and has been performing clinical trials for over 30 years. The company is headquartered in Hoppegarten near Berlin, Germany.
The Center of Phytochemistry was set up as a joint project of the Bulgarian Government, UNDP, and UNESCO for scientific and applied research and training of specialists in organic chemistry and chemistry of natural products. The organization was renamed The Institute of Organic Chemistry with Centre of Phytochemistry (IOCCP) and is the leading scientific institution in t organic and bio-organic chemistry field in Bulgaria. VIRO has engaged IOCCP, represented by Prof. DSc Pavlina Dolashka, a member of its organizing committee and scientific committee to perform the biochem analysis of ITV-1 at the Bulgarian Academy of Science.
Documentation and correspondence that is required with the EMA as part of the permitting and application process will be performed for VIRO by Vili Topalova, MD EU QPPV Medical Director of AV Consult Pharm ("AVCP"). AVCP is a consulting company in the fields of Regulatory Affairs, Pharmacovigilance, Medical Devices vigilance, Cosmetovigilance, price and reimbursement and other consultancies for medical treatments. AVCP's expertise is based on years of experience with the Bulgarian Drug Agency (BDA) and the technical expertise of its employees – former experts and employees of the Bulgarian Drug Agency (BDA).
As a result of a delay in delivery of the Toxicity report to the African hospitals, GOMA, PRC, and Panzi Hospital, Bukavu, DRC, the administration of the ITV-1 immunotherapy initial injections into the HIV/AIDS-infected volunteers was delayed. We expect that to commence soon.
Since entering the U.S. Market six months ago, VIRO's growing nutraceutical division has resulted in the exclusive distribution licensing of + Liver Rescue™ in the North American market. This product accelerates the functions of the liver (accelerated emission of alcohol dehydrogenase), thereby reducing the harmful effects of alcohol on the body and the central nervous system. This is a new revolutionary nutritional supplement in the form of a drink, which is currently being marketed in Europe with great success. Coupled with the monthly increasing production and sales of IPF Immune™, the market potential for these products is favorable.
Currently, the Company is pursuing testing IPF Immune as an immunomodulator under EMA guidelines on patients with cirrhosis, as an after-radiation and chemotherapy treatment of cancer patients in an attempt to reduce recovery time from the effects, impact on HIV patients immune system (in addition to the ITV-1 Clinical trials), application for type 2 diabetes patients effect on blood sugar levels and glycosylated Hb (in addition to the clinical trials of ITV-1 as a treatment for type 2 diabetes scheduled for later this year), herpes, COVID, influenza and all diseases where there is an immune system decline - including autoimmune disease. With the potential of both ITV-1 and IPF Immune to participate in the aforementioned markets, capturing 1% of the 2022 autoimmune $104.21 billion market and the $84.56 2023 diabetes market, VIRO could realize over $2 billion in revenue in addition to what it captures in the HIV/AIDS $30.46 billion market where VIRO expects the most significant market penetration.
VIRO has also filed two utility patent applications covering its new developments, one covering the European Union and one for the United States.
“With the quality of our partners and our past success with ITV-1 Clinical trials, we at VIRO are expecting great success in not only the ITV-1 application to HIV but also its application to Diabetes and other areas being pursued,” stated Harry Zhabilov, CSO of VIRO.
ENZC has provided SAGA with its draft of the Business Combination Agreement and related documents and is awaiting any edits or comments in anticipation of a final version being circulated for signature by October 31, 2023.
Barry Kostiner, CEO of Sagaliam, commented, “We are continuing to make progress on the consummation of our transaction with Enzolytics. The deep bench of expertise and therapeutic solutions is impressive. In addition to our dedicated scientists, we have an outstanding team of collaborators who support all aspects of the business including regulatory, clinical and manufacturing operations. The goal is to build a pharmaceutical platform company, going beyond one-off therapies, to providing solutions for broad categories of chronic disease.”
The above was copied from Enzolytics web site .
I would say they kept us somewhat updated then nothing on Africa after thet say they got the importing clearance. If anyone has a different update please post. GLTA
Correct thanks Timing A/S .
Hopefully it is for and will be used for a good reason. Time will tell. GLTA
Not sure what you are saying , can you dumb it down for us or show what you are talking about on pacer. Thank you
Glad you are still doing well , you really haven't missed anything that would move the neddle as you can see the SP is about where it was a year ago. Stay healthy and enjoy life. Hopefully we will meet at the club soon rather than later. GLTA
Another thing to keep in mind they raised the O/S by 900m awhile back why? We were never told exactly why, but it was done for a reason. If the float is low why would they need another almost billion to work with.
All above our paygrade, it is now a wait and see what they actually can provide to the world as a treatment and cure. GLTA
Yes 1/100 on Oct 12
Totally agree
Can you see that by the trade volumes why their is more shares than what you think is in the float. That 2020 was conversions happening and bad debt deals flooded the market then along came pump fest for the run up.
Here we are today a ton of shares being held and no driving force other than when MM's are told let it run for awhile and then bring it back to a certain level of trading. Go back and look at any small run volume in the 25-40m range then it is gone and we drop and back in a .03-.06 range with 1.5-3.5m volume. MP has shown the pattern for years , it is not common what we see with this stock for aslong as it has been happening..
Case in point a few weeks maybe even a month ago TTOO released info and ran up from pennies to double digit dollars then dropped down.
don't you think if shareholders could control the drop of SP they would have Below is the company they just did a reverse split on the 12th so numbers look really crazy but you can back calucalate to see what it was exactly. They had to do it to meet NASDAQ requirements they weren't meeting with SP.
The stock price of T2 Biosystems Inc (TTOO) is $6.11 as of October 19, 10:10 AM EDT1. The stock has a 52 week high of $234.76 and a 52 week low of $5.41. The market capitalization of the company is $20,381,7381. The stock has an accumulated volume of 325,429 and an average volume of 1,082,7721. The stock price has decreased by 9.2125% in the last trading session1.
https://finance.yahoo.com/quote/ENZC/chart?p=ENZC#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
look around sept 2020 thru Oct
About the the price drop , why does every company when dilution takes place and or debt conversions happens it drops , because they have unlimited shares practically at .0001 so if they dump at .01 or even .05 below current share price either the holders keep holding or sell at a lower cost, enough share and they keep dropping the price it will fall. That is what happen when this ran and people started taking profits no matter what it sold at because at that point they were killing it.The ones that held are the bag holders because the price has dropped so much they dont want a real lose they would rather hold hoping it goues up at some point. Either they ride it all the way down or cut their loses and get out. Just because their is a large amount being held that will not stop a massive dump of .0001 shares hitting the market to thoses companies anything is a profit the common investor doesnt stand a chance which at that point we hope the MM's dont take it to low. The MM's get their money buy doing what thoses holding the large coversion dumps wants. At that point the common investor either buys cheapies, average down or holds for another day either way we can't control it.
About the price should go up on news we all agree that is why people are saying this is being controlled one way or the other. News comes out it goes down,MMScontrol processing the orders nothe the sharholders. As i have mentioned many here have had orders go unfilled and orders below ours filled. That shouldnt happen but has it is the OTC
That is the best I can tell you.
Not going to argue with what the exact amount of the float is , I am going with 2.3B or so . The reasoning is go back and look at the bad debt deals that were made which has caused all the issues. Their were loans that gave 100m shares @ .0001 to many lenders for small amount of cash in return. That alone will exceed the 400-600m shares making the low float # being thrown out there. When they converted they now are own by many of us maybe even you. The law suit with Dimiter Savov alone is over 70m. The restricted shares are factored out bringing the float to that 2.3B # people are using.
O/S at 3.3B at last update and A/S at almost 5B. The runup had volume trading of over 1.4 to 1.7B for days and 350-700m for a week. So with that volume are you saying only 400m were traded over and over with no one holding everyone was flipping shares to do 1.7B in a day. That is why most people are saying dividend will be paid out using a 2.2B est of the O/S shares. I did not make up the volume traded in Enzolytics it is easy to go back on any chart for a 5 year period and see the SP and volume for any day.
Hope this helps explain why people are in agreement that approx 2.3B will used as the factor to 36M shares ratio.We all probably are hoping you are right with the 400-600m float and we get alot more shares, but even their own example was showing approx 900 shares per 100k shares held.
Thats all I got to explain my thinking so now we will just wait to see how it all plays out GLTA
True that thing is Ugly for 120k+, and that was another thing that was messed up , 2 models that came after the original orders were taken were being delivered to dealers before ours had even been given a production date. Ford messed that whole launch .
Here are some more videos for all to relive them again GLTA
Question Are your boards getting smaller as people win the award ( IGNORE ). Mine is getting there , the reads stay on topic alot better. Thanks to all that are keeping it real for the longs and for the new ones that have the right to see true DD , facts and then compare to what is out there, whats on the official websites, and actual new sources that are proven and not just a pay to have a puff piece done on the company. Like many here have stated info is out there do your own research verify what you found and double check the source. OTC is not a forgiving trading area to learn in, unless you control and understand the information research you are using. Don't be scared to ask questions , then double check what has been passed on to you by others. Not writting to scare a new investor instead giving facts for them to do DD for themself and make their decisions GLTA
Hey Jim
Hope all is going well and you have been visting friends thruout the USA. I know you said you had a timeline , and it is running out soon. Are you going to hold out to see what comes from this vote , SEC ruling on SAGA, and NASDAQ or just going to wait for another .12 or better rise in price and selloff all or half. I am thinking half for me, unless some real news is confirmed volume really picks up then I might ride it for awhile but will sell if it starts that dreaded drop. GLTA
I gotcha ya , alot of info was being put out by him when this was rocking and rolling, and most things we are still waiting on. I do get what you are saying about jailbird. GLTA
Dyno come on they don't want to see facts. When presented with them they go silent or do that thing deflect so people don't catch on that they are the ones trying to get cheapies. GLTA
Agree with the replies , funny how facts just keep getting put out and crickets.
GF has noway to explain it , that is why he isn't going to try. Funny thing is what is the difference of what he has put out and that guy that went to jail pumping a stock a little while ago.Debarg or something like that. Feel free to post to discord what I posted about the video with questions and see if any of them can find away to spin it.
Like Enzolytics told everyone awhile back if it doesnt come from them don't believe it. Then you have to even question that due to their own statements , which has been posted but it is our fault because it didn't fit our timeline. Sorry but just like the Ford launch of the Bronco I guess thoses same people would blame the buyers for Ford taking 2 years to deliver orders that they took. That is another fact because I ordered one Oct 2020 and didnt get it until Oct 2022 but I got a lithograph, playing cards and other BS stuff and an apology letter for the delay. GLTA
Just rewatched and it is the same logo closing on both videos gotta be true, so is it an Enzolytics promo for the company they are selling off or is it just another video we should take to the bank? Has anyone asked GF how the team got their shares when the deal has yet to be finalized and announced offically?
If the deal is done then we should be on the 6 month countdown and the mystical date will be revealed when it was signed and eligablity for the dividend date started. To keep the lines from blurring the SPAC aslong as the deal was signed dated by 10-23-2023 the time to go thru the finializing the end of the SPAC could go past that date, as they have stated and many on this board as described. So if it is done the need to extend it any futher would not be needed thru late 2024. What are we missing? Lack of funding the deal actually isn't completed, if so how did they receive shares that were based on the deal being completed. GLTA
Nice video , got one here to look at and take notes on the dates they put out , lets just keep it real and see what actually happens. Look at who posted that one back in the day GLTA
Yes, outstanding shares are the shares of a company that are currently owned by investors and have not been repurchased by the company. If a company chooses to pay dividends, every share outstanding is qualified to receive dividends1. The dividend per share is the sum of declared dividends issued by a company for every ordinary share outstanding. The figure is calculated by dividing the total dividends paid out by a business, including interim dividends, over a period of time, usually a year, by the number of outstanding ordinary shares issued1. Therefore, dividends are paid on outstanding shares. I hope that helps!
Learn more:
1. investopedia.com
2. bing.com
Yes I agree with that I was just asking what he was stating if my numbers were right with how he broke it down to. yeah that is what I am planning on a dividend of about 436k then hoping it holds , nothing near what any of else were planning on from shares of Enzolytics being worth meaning alot more for ENZC shares if one holds a nice amount GLTA
DRHUMI So I have 4m shares are you proposing I would get 360k shares of SAGA? so basicaly 3.6m dollars with the shares being 10 a share. If so none would have a problem with that. It is not what their made up example came out to be it was more like 900-1200 shares of SAGA for every 100,000 share you hold of Enzolytics.
Going back to the vote , still trying to understand how the Enzolytics management team got shares awarded to them before the deal is done, noone has been able to answer that. If the deal is done then SAGA in violation of disclosures that would have had to be filed or am I missing something? They are on NASDAQ and have require filings by SEC rules changing controlling factor of shareholders is one of them. Would the investors of two years in this SPAC be a little pissed if what is being post is true that Barry just stacks shareholders to load a vote. GLTA